Skip to main content
Equibles
NHP logo

NHP · National Healthcare Properties, Inc. · Metrics

Track NHP — free

Use NHP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NHP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.63 -0.17 (-1.08%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.15B
Shares
72.90M
Volume · Oct 23 41.96K Avg daily vol (3M) 773.44K

NHP metrics

74 of 126 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$15.80
Market cap
$1.15B

Price action

20 metrics
Price change (1W)
+5.0%
Price change (30D)
-3.1%
Price change (3M)
-0.2%
Price change (6M)
+26.4%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
35.9%
Annualized volatility (3M)
30.1%
Beta
0.0
RSI (14D)
53.3
Price vs SMA 50
-1.3%
Price vs SMA 200
—
Avg volume (3M)
773,436
Relative volume
3.0
Average dollar volume
$12.30M

Company

3 metrics
Sector
Real Estate
Industry
REIT - Healthcare Facilities
Shares outstanding
72.90M

Valuation

14 metrics
P / FFO
58.9×
Company-stated · FY2025 · reciprocal yield 1.7%
P / AFFO
—
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.1×
reciprocal yield 32.0%
P / book
1.0
reciprocal yield 98.0%
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
21.2
reciprocal yield 4.7%
Earnings yield
-4.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
0.9%
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
$0.15
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
2026-10-09

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
37.9%
Operating margin
3.2%
Trailing 12 months
Net margin
-13.1%
Gross profit (TTM)
$130.42M
Operating profit (TTM)
$10.99M
Net income (TTM)
−$45.00M
Trailing 12 months
Diluted EPS (TTM)
$-1.88
FCF margin
—
Effective tax rate
—

Per share

13 metrics
FFO per diluted share
—
AFFO per diluted share
—
Revenue per diluted share (TTM)
$10.49
Gross profit per diluted share (TTM)
$3.97
Operating profit per diluted share (TTM)
$0.29
EBITDA per diluted share (TTM)
$2.48
Net income per diluted share (TTM)
$-1.49
Operating cash flow per diluted share (TTM)
$1.38
Free cash flow per diluted share (TTM)
$1.29
Capital expenditures per diluted share (TTM)
$0.71
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.16
Book value per share
$20.84

Growth

11 metrics
Revenue growth YoY
+2.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$344.32M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+117.7%
Year over year · more shares
Revenue CAGR (3Y)
+0.6%
Revenue CAGR (5Y)
-2.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
-24.5%
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-4.3%
Return on assets
-2.3%
Debt / equity
—
Current ratio
—
EBITDA (TTM)
$82.55M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
0.2
Net debt / EBITDA
-3.0
Return on invested capital
—
Trailing 12 months
Net cash
$245.69M
Latest balance sheet
Cash & equivalents
$245.69M
Total assets
$1.98B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$50.75M
Capital expenditures (TTM)
$16.72M
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$5.42M
R&D / revenue
—
Stock compensation / revenue
1.6%

Ownership (13F)

9 metrics
13F filers
94
13F filer change QoQ
+94
Institutional ownership
73.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
1.0
Price vs estimated holder cost
+4.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.0%

Short interest

3 metrics
Short interest
4.6%
Latest settlement · 3.4 days to cover
Days to cover
3.4d
Short-squeeze score
62 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1561032 CUSIP 42226B501 13F (30d) 11 filings 11 filers Visit website Investor relations